Up 45% in 2012 and nearly 70% in the past 12 months, Danish pharmaceutical company Novo Nordisk (NYSE:NVO) has outpaced its peers by a wide margin. Novo's performance has been fueled by an incredibly concerning trend, the growing incidence of diabetes worldwide. As the leader in insulin -- a must-have for Type 1 diabetes patients and a growing need for many Type 2 diabetics -- the company is well-positioned to capitalize on this secular trend.

In the following video, health care bureau chief Brenton Flynn and analyst David Williamson discuss some more positive news for Novo Nordisk, as well as an important date for investors to be aware of next month. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.